Merz Therapeutics
NC - RaleighBiotechnology
Focus: Merz Therapeutics is a specialty biotech focused on small-molecule therapeutics across neurology, metabolic diseases, cardiovascular, and infectious disease indications, headquartered in Raleigh, NC. The company derives 59% of revenue from AMPYRA (dalfampridine), a potassium channel antagonist for multiple sclerosis.
Profile data last refreshed 7h ago · AI intelligence enriched 3w ago
Open Jobs
3
Should You Work at Merz Therapeutics?
AI assessmentMerz Therapeutics offers near-term stability from established products but faces significant patent cliff exposure and limited hiring, making it a risky mid-career choice absent major pipeline inflection.
Why Work Here
- Established revenue base with two marketed products (AMPYRA and INBRIJA) generating $71M in Part D spending, providing revenue stability for operations.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$44MDeclining
LOE Approaching
Revenue anchor generating 59% of company sales but facing exclusivity cliff without disclosed protection date.
Help build intelligence for Merz Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.